All In Biotech

Drug Trial Radar · NCT06621563

Phase Ib Trial of HS-20117 in Combination With Other Drugs in Advanced Solid Tumors

Safety, Tolerability, Efficacy, Pharmacokinetics Profile and Immunogenicity of HS-20117 in Combination With Other Drugs in Advanced Solid Tumors, a Phase Ib Clinical Trial

Last checked: Nov 19, 2026Latest source record: Apr 9, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

780

Planned (sponsor's estimate)

Start

Dec 14, 2024

Primary completion

Mar 30, 2026

Study completion Dec 1, 2026

Sponsor

Lead sponsor
Hansoh BioMedical R&D CompanyIndustry
Sponsor type
Industry
First posted
Oct 1, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

HS-20117 is a fully-human EGFR-MET immunoglobulin G1(IgG1)-like bispecific antibody. The purpose of study is to evaluate the safety, tolerability, efficacy, PK profile and immunogenicity of HS-20117 in combination with other drugs in advanced solid tumors.

Conditions

  • Solid Tumors
  • Non-Small Cell Lung Cancer
  • Colorectal Cancer

Interventions

  • HS-20117 combined HS-20093Drug

    HS-20117 + HS-20093

  • HS-20117 combined Platinum-containing chemotherapyDrug

    HS-20117 + cisplatin/carboplatin + pemetrexed

  • HS-20117 combined HS-20093 and 5-FUDrug

    HS-20117 + HS-20093 + 5-FU

  • HS-20117+CAPEOXDrug

    CAPOEX: Oxaliplatin+Capecitabine

  • HS-20117+FOLFIRIDrug

    FOLFIRI=Irinotecan+Leucovorin Calcium+5-FU

  • HS-20117+mFOLFOX6Drug

    mFOLFOX6=Oxaliplatin+Leucovorin Calcium+5-FU

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence and severity of treatment-emergent adverse eventsTime frame: rom the date of first dose to 90 days after the final dose.
  2. Tolerability of HS-20117 combination therapy: incidence of DLT events, maximum tolerated dose (MTD) or maximum applicable dose (MAD) of HS-20117 in combination therapies.Time frame: From the date of first dose to day 21.

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Tianjin Medical University Cancer Institute & Hospital

    Tianjin, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.